Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NS 2330 add-on to donepezil in mild to moderate Alzheimer's disease
2004-001100-12Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tesofensine in Alzheimer's disease (AD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Safety and tolerability of NS 2330 added to donepezil over 14 weeks. Started Jun 2004; status: completed.
02
Drugs
tesofensine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2004-001100-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001100-12.